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ABSTRACT 
Streptococcus agalactiae or Group B Streptococcus (GBS), is a Gram-positive 
commensal bacterium that is harmless in healthy adults, yet causes systemic diseases in 
neonates, the elderly, and immunocompromised individuals. Neonates are at risk of GBS 
infection in utero or during delivery due to the colonization of the organism in the vaginal 
canal of between 15-30% of adult females. GBS can cause severe neonatal sepsis and 
meningitis, as well as chorioamnionitis, which can cause premature birth and stillbirth. 
GBS infection is greatly facilitated by the presence of a bacterial capsule; a protective, 
polysaccharide matrix surrounding the cell that plays a key role in the pathogen’s ability 
to evade host immune responses. Antibiotics are effective in reducing the chances of 
neonatal infection by GBS; however, they also increase the likelihood of the organism 
developing antibiotic resistance. An approach to manipulate GBS and reduce its 
functionality would be beneficial to counter the potential of antibiotic resistance 
developments, while avoiding the cytotoxic effects that antibiotics can impose on the 
host. 
The GBS CpsA protein, a putative transcriptional regulator of the capsule locus 
within the GBS genome, plays a significant role in capsule production. Without CpsA, 
GBS displays reduced capsule production, and thus, reduced virulence. In this study 
Aspartic Acid-375 and Arginine-378 were targeted in the LytR domain of CpsA, a 
domain proposed to be responsible for the ligation of capsule to the cell wall of GBS. 
This work will provide insight into which amino acids are the key residues required for 
the function of CpsA.
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1. INTRODUCTION 
1.1 Streptococcus agalactiae 
Streptococcus agalactiae, or Group B Streptococcus (GBS), is a Gram-positive 
commensal bacterium that normally grows in short chains of two to five cocci (1). In 
approximately 30% of healthy adults, GBS is an asymptomatic colonizer of the 
gastrointestinal tract, genitourinary tract, and additionally in women, the vaginal canal 
(2). Although asymptomatic and harmless in healthy adults, GBS is an opportunistic 
pathogen that can cause systemic diseases in neonates, the elderly, and 
immunocompromised individuals (3). Regardless of modern prophylactics, GBS is the 
leading cause of neonatal sepsis in high-income countries (4). In newborns, GBS can also 
cause meningitis, chorioamnionitis, and pneumonia (5). GBS infections are also a cause 
of preterm delivery, antepartum and postpartum stillbirth, and puerperal sepsis (6). 
Neonatal infection by GBS can be characterized as either being early-onset or late-onset. 
Early-onset GBS infections (0-6 days) stem from vertical transmission of the pathogen 
from mother to child before or during delivery through bacterial particles present within 
the amniotic fluid. Late-onset GBS infections (7-89 days) occur after delivery and are 
acquired from the mother or the environment (7). Current practices to reduce 
transmission of GBS to newborns include screening and intrapartum antibiotic 
prophylaxis using penicillin (8). Despite being effective, antibiotic administration can 
pose major threats to the development of both the newborn’s gut microbiota as well as 
their immune system (9). 
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1.2 Peptidoglycan 
Gram positive organisms, such as GBS, contain a cell wall consisting of a thick 
peptidoglycan layer, cell wall-associated teichoic acids, capsular polysaccharide (CPS) 
and other associated proteins. The peptidoglycan of the cell wall is made up of repeated 
N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM), with several peptides 
and proteins attached via cross-linking or covalent and non-covalent interactions. The 
thick peptidoglycan layer also plays a major role in protecting the bacterial cell 
membrane. Importantly, anionic teichoic acids are scattered throughout the 
peptidoglycan, functioning to provide cell wall integrity, as well as granting the cell 
surface an overall negative charge (10). The peptidoglycan primarily acts as a scaffold for 
adherence and/or anchoring for several proteins and peptides. Many of these cell wall-
associated proteins interact with the extracellular environment, working to maintain the 
functionality of the cell, while also protecting the cell from external threats. A major 
player in the protection of GBS is the capsular polysaccharide (CPS), which acts as the 
outermost layer of the cell surface, providing the cell with additional protection and 
structural integrity (11). 
1.3 Group B Streptococcus Capsule 
GBS infection is primarily facilitated by the presence of a bacterial capsule, a 
protective, polysaccharide matrix surrounding the cell that plays a key role in the ability 
of the pathogen to evade host immune responses, to bind to host cells, and to penetrate 
host tissues. The GBS capsule consists of capsular polysaccharides (CPS) which are 
covalently bound to the N-acetylglucosamine peptides of peptidoglycan (10). The 
enzyme(s) that covalently add and ligate CPS to the N-acetylglucosamine peptide have 
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not been determined in GBS and therefore elucidating the enzymatic process is one of the 
key objectives of this study. There are approximately nine antigenically distinct serotypes 
of GBS CPS, each consisting of various arrangements of galactose, glucose, GlcNAc, and 
sialic acids, such as N-acetylneuraminic acid (12). N-acetylneuraminic acid, commonly 
found in human and mammalian cells, allows for GBS to employ host-cell molecular 
mimicry, a means of avoiding recognition and phagocytosis by host immune cells (13).  
The production and regulation of GBS capsule is key to the virulence and survival 
of the organism. CpsA is a putative transcriptional regulator protein of the capsule locus 
and is likely responsible for GBS capsule synthesis and ligation to the outer cell wall (1). 
 
1.4 CpsA Protein 
CpsA is a putative transcriptional regulator of the capsule locus in the GBS 
genome and is encoded by cpsA. This protein is common to all serotypes of GBS and 
belongs to the LytR-CpsA-Psr (LCP) protein family. The LCP protein family is 
associated with cell wall maintenance, stability, and carbohydrate linkage (1). The CpsA 
protein contains an intracellular DNA-binding domain, three transmembrane domains, an 
extracellular accessory domain, and an extracellular LytR domain (Figure 1). The LytR 
domain is a putative phosphotransferase that is likely involved in capsular attachment and 
cell wall stability. The CpsA protein is highly conserved in other Streptococcus species, 
including Streptococcus pneumonia and Streptococcus iniae, and is shown to play a 
bifunctional role in capsule expression and cell wall stability (1). 
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Figure 1. CpsA protein structure. Diagram displaying the DNA-Binding domain (N-
terminus), three transmembrane domains (red), Accessory Domain (Purple), and LytR 
Domain (Green). 
1.5 Previous Research 
The CpsA protein has been demonstrated to regulate the transcription of the 
capsule locus (10), although the mechanism of this is not known. Previous research 
showed that the deletion of cpsA in S. agalactiae and S. iniae resulted in a myriad of 
pleiotropic effects (14). The deletion caused a decrease in levels of CPS production and 
microscopy analysis revealed that ΔcpsA GBS displayed a long-chain phenotype. 
Whether the long-chain phenotype is a result of decreased capsule is unknown, however 
it is predicted that CpsA-dependent changes to the cell wall are responsible for 
differences in chain lengths between wild-type and ΔcpsA GBS (1). 
CpsA plays a vital role in the virulence of GBS. Rowe et al, demonstrated that in 
the absence of CpsA, GBS virulence was attenuated in a zebrafish model. Zebrafish were 
inoculated with a wild-type strain of GBS 515, and after six days post-infection only 8% 
survived. This was compared against ΔcpsA GBS 515-inoculated zebrafish, which after 
six days post-infection displayed a viability of 68% (1). 
Cps2A is a Streptococcus pneumoniae protein analogous to CpsA. Both proteins 
are highly conserved (50% identical and 69% amino acid similarity), with exceptions to a 
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few differences in amino acids (1). Kawai et al, was able to characterize the Cps2A 
protein and solve the crystal structure to visualize the two extracellular domains (Figure 
2). The goal of the study was to determine Cps2A functionality through the visualization 
of the folded protein structure and its amino acid residues (11). The crystal structure 
displays that both the Accessory and LytR domains fold independently of one another 
and that a buried decaprenyl-phosphate lipid is present in the LytR active site. The 
function of the buried lipid is not known; however, it may play an integral part in the 
ligation of CPS to the cell wall. Key residues that interact with the phosphate headgroup 
of the decaprenyl-phosphate lipid to maintain its stability are R267, R362, and R374 
(Figure 3). These residues form key interactions with the phosphate oxygens to create a 
positively charged pocket in the surface of the protein (11). D371 and Q378 interact with 
the arginine residues to stabilize their conformations (Figure 3). In GBS, these residues 
are shifted slightly, but are predicted to maintain similar interactions. 
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Figure 2. Crystal structure of Cps2A extracellular domains in Streptococcus 
pneumoniae. The Accessory Domain (red) folds separately from the LytR Domain 
(green). The LytR Domain displays a buried decaprenyl-phosphate (carbon atoms are 
yellow, phosphorous is orange, and oxygen is red) (11). 
 
 
Figure 3. Lipid binding by the LCP domain of Cps2A in Streptococcus pseudomonas. 
Figure displays the decaprenyl-phosphate binding to Cps2A, as well as the two key 
residues of this study: D371 and R374 (D375 and R378 in GBS) (11). 
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1.6 Research Objective 
The primary objective of this study is to gain insight into the functions of CpsA 
through LytR mutations. To test the hypothesis that there are key amino acid residues of 
the LytR Domain essential to the functionality of CpsA, point-mutations at Aspartic 
Acid-375 and Arginine-378 (correlating to D371 and R374 in S. pneumoniae) of the LytR 
domain will be generated in GBS. The effects of these point mutations will help elucidate 
the functions of key residues within the LytR domain and help determine if they are 
essential for GBS capsule production or capsular attachment to the cell wall. The findings 
of this study may contribute to future medical approaches to treating and preventing GBS 
infections. In determining which amino acids are essential to CpsA and capsule 
regulation, researchers could develop a targeted therapy that reduces GBS virulence and 
promotes the normal function of the innate immune system. 
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2. MATERIALS AND METHODS 
2.1 Plasmid Construction 
2.1.1 Plasmid Preparation 
 The pLZ12-rofA-pro shuttle vector (can replicate in E. coli and Streptococci) 
containing a Chloramphenicol resistance marker was provided by Dr. Melody Neely 
(University of Maine, Orono, Maine, USA). The plasmid underwent a restriction enzyme 
digestion in order to prepare it for ligation. The plasmid was digested with BamHI and 
PstI and was verified to be ~4500bp by gel electrophoresis on a 0.8% agarose gel. The 
digested plasmid was then gel isolated using a GeneJET Gel Extraction Kit 
(ThermoFisher Scientific). 
 
2.1.2 Splicing by Overlap Extension – Polymerase Chain Reaction (SOE-PCR) 
cpsA mutations D375A and R378A were created in the cpsA gene of GBS using a 
three-reaction PCR procedure (SOE-PCR) to create a mutant cpsA fragment. The first 
PCR used GBS genomic DNA as template with primers 5’ GBS-CpsA-RBS-BamHI and 
3’ CpsA-D375A-R378A and Q5 High-Fidelity DNA Polymerase. Following the PCR, the 
reaction was verified to be ~1145bp using gel electrophoresis on a 0.8% agarose gel and 
the band was extracted and purified using a GeneJET Gel Extraction Kit (ThermoFisher 
Scientific). The purified mutant cpsA DNA fragment (Fragment 1) was stored in a 1.5mL 
microcentrifuge tube at 4℃. 
The second PCR used GBS genomic DNA as template, primers 5’ CpsA-D375A-
R378A and 3’ GBS-cpsA-full-PstI and Q5 High-Fidelity DNA Polymerase (New 
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England BioLabs). Following the PCR, the reaction was verified to be ~350bp using gel 
electrophoresis on a 0.8% agarose gel and the band was extracted and purified using a 
GeneJET Gel Extraction Kit (ThermoFisher Scientific). The purified mutant cpsA DNA 
fragment (Fragment 2) was stored in a 1.5mL microcentrifuge tube at 4℃. 
 In the final PCR, a SOE reaction was performed to create the full mutant cpsA. 
Fragment 1 and Fragment 2 were used as template with outside primers 5’ GBS-CpsA-
RBS-BamHI and 3’ GBS-cpsA-full-PstI and Q5 High-Fidelity DNA Polymerase (New 
England BioLabs). Following the PCR, the reaction was verified to be ~1470bp using gel 
electrophoresis on a 0.8% agarose gel and the band was excised and purified using a 
GeneJET Gel Extraction Kit (ThermoFisher Scientific). Once purified, the full-length 
mutant cpsA fragment was digested with BamHI and PstI using the same protocol as 
listed in 2.1.1 Plasmid Preparation. The digested mutant cpsA DNA fragment was then 
ligated with the digested pLZ12-rofA-pro vector from protocol 2.1.1. In addition, a 
negative control consisting of just the digested vector and no mutant cpsA was also 
ligated. The ligation reaction mixtures were incubated at room temperature for 30 
minutes. After the ligation reactions, any remaining salts in the products were removed 
using butanol precipitation. 
  
2.1.3 Electrotransformation of Escherichia coli 
 Competent Escherichia coli were provided by Dr. Melody Neely (University of 
Maine, Orono, Maine, USA) and used as a primary means of transformation to complete 
the previous ligation reactions and seal any DNA nicks. 40 microliters of electro-
competent E. coli cells were mixed with 5uL of the ligated mutant cpsA plasmid 
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Electrotransformation was performed using a Gene Pulser II Electroporation System 
(BIO-RAD) set to 2.5µm, 2.5kV, and 200Ω. The electroporated cells were immediately 
transferred into 1 mL of SOC medium and incubated at 37℃ for 1.5 hours in a shaking 
water bath. Following the incubation, the transformant groups and negative control were 
plated on LB agar plates supplemented with Chloramphenicol (20µg/mL) to select for 
transformants. 
 
2.1.4 Colony PCR and Plasmid Analysis 
 Several transformed colonies were selected and used in a colony PCR to confirm 
the presence of the cpsA gene using Dreamtaq Green PCR Mastermix (ThermoFisher 
Scientific) and primers 5’ GBS-CpsA-RBS-BamHI and 3’ GBS-cpsA-full-PstI. After 
performing the colony PCRs, the reactions were verified for size through gel 
electrophoresis on a 0.8% agarose gel. Band length results were compared against a 1kb 
ladder, and a positive and negative control. Colonies that were verified to contain the 
mutant cpsA plasmid were inoculated into Luria Broth (LB) with Chloramphenicol 
(20ug/mL) and used in a plasmid preparation using the Hi-Pure Plasmid Midiprep Kit 
(ThermoFisher Scientific). Following plasmid isolation, the concentration of each 
plasmid DNA was analyzed using a NanoDrop OneC Microvolume UV-Vis 
Spectrophotometer (ThermoFisher Scientific). The products were then sequenced by 
Patty Singer (University of Maine Sequencing Facility, Orono, Maine, USA) to verify 
that the mutant plasmid contains the D375A and R378A mutations and no other 
mutations in the cpsA sequence. 
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2.2 Electrotransformation of Streptococcus agalactiae 
 Wild-Type and ΔCpsA Group B Streptococcus 515 cultures were grown 
overnight at 37℃ in Todd-Hewitt Yeast Broth (THYB) supplemented with 80 mM of 
Glycine. The overnight cultures were then diluted into 25mL of THYB supplemented 
with 80 mM of Glycine at a dilution rate of 1:20. The subcultures were grown in a 
shaking water bath at 37℃ to an OD600 of 0.400 and then harvested by centrifugation, 
washed three times with 10 mL off chilled 10% glycerol, and resuspended in 1mL of 
chilled 10% glycerol, followed by incubation on ice. The mutant plasmid was 
transformed into Wild-Type GBS 515 and into ΔCpsA GBS 515 using 3uL of the 
plasmid DNA and 200uL of the GBS cells. Electroporation was performed with a Gene 
Pulser II Electroporation System (BIO-RAD) at 25µm, 2.0kV, and 400Ω. The 
electroporated cells were immediately transferred to 10mL of fresh THYB medium and 
allowed to recover for 90 minutes at 37℃ before plating on THY agar with 3ug/mL of 
Chloramphenicol. Two negative controls were also electroporated, consisting of either 
Wild-Type or ΔCpsA GBS 515 cells and no added plasmid. 
  
2.3 Microscopy 
Light microscopy was performed on Wild-Type GBS 515, ΔCpsA GBS 515, 
Wild-Type GBS 515 + pCpsA Mutant, and ΔCpsA GBS 515 + pCpsA Mutant strains 
using a compound microscope (Zeiss Axiostar), visualized at a magnification of 1000X. 
Five fields of view for each strain were saved in JPEG format and the average cocci per 
chain was calculated manually. 
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2.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
 Overnight cultures of each experimental strain (Wild-Type GBS 515, ΔCpsA 
GBS 515, Wild-Type + mutant plasmid, and ΔCpsA + mutant plasmid) were grown in 
10mL THYB supplemented with Chloramphenicol(3ug/mL).  
Pre-absorption of the secondary antibody was performed by mixing 2.5mL of 
both Wild-Type and ΔCpsA GBS 515, followed by centrifugation and resuspension in 
1mL of Tris-Buffered Saline (TBS). Secondary antibody (goat, anti-rabbit IgG 
conjugated to alkaline phosphatase) was added at a 1:100 dilution and incubated at 4℃ 
for 1 hour on a rotator. After the incubation, cells were pelleted by centrifugation and the 
supernatant was collected and filtered with a 0.22µm syringe filter. This resulted in 
obtaining ~1mL of 1:100 pre-adsorbed secondary antibody. 
 The remaining overnight cell cultures were normalized to an OD600 of 0.750. 
Normalized samples were then pelleted via centrifugation, resuspended in 1mL TBST, 
and vortexed. The samples were pelleted again via centrifugation and resuspended in mL 
TBST. Primary antibody (rabbit - anti-serotype 1a) at a final dilution of 1:20,000 was 
added and incubated at 4℃ on a rotator for 1 hour. Cells were pelleted via centrifugation 
and washed three times with TBST, vortexing after each wash. The cells were 
resuspended in 1mL of TBS-T. Next, the pre-adsorbed secondary antibody was added to 
each cell sample to a final dilution of 1:5,000. The cell samples were then incubated at 
4℃ for 1 hour on a rotator. Following the incubation, cell samples were pelleted via 
centrifugation and then washed three times with TBST. The cells were then resuspended 
in 1mL of TBS-T. Following this, an alkaline phosphatase assay was performed on all 
reactions in a 96-well plate, using pNPP as substrate and 50uL of cells per well. Assays 
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were performed in triplicate at no dilution, a 1:2 dilution, and a 1:4 dilution. Following 
the addition of cells and pNPP to each well, the contents of the 96-well plate were 
incubated in the dark at room temperature for 1 hour. The plate was then read at OD405 
and OD600 using a 96 Microplate Reader (VersaMax). 
 
2.5 Fluorescent Vancomycin Assay 
 Overnight cultures of negative control groups (Wild-Type GBS 515 and ΔCpsA 
GBS 515) and mutant plasmid cpsA in GBS 515 Wild-Type and ΔCpsA, were grown in 
THYB with 3ug/mL of chloramphenicol). Overnight cultures were subcultured into 
THYB+Chloramphenicol (3ug/mL) and grown to mid-log phase (OD600=0.300). The 
cultures were then concentrated to an OD600 of 1.0. Ten microliters of the cultures were 
incubated with 1ug/uL of BODIPY_FL Vancomycin (ThermoFisher Scientific) at 37℃ to 
allow for the incorporation of the fluorescent stain into newly formed cell walls. The cell 
cultures were then washed three times in Phosphate-Buffered Saline (PBS) and then 
resuspended in 3uL PBS. Cells treated with fluorescent vancomycin were observed as a 
wet mount at 1000X on a fluorescent microscope (Zeiss Axiostar). 
 
2.6 Zebrafish Immune Response Assay 
2.6.1 Preparation  
Zebrafish were bred and 2-day old embryos were used for infections. The day 
before injecting zebrafish larvae, overnight cultures of Wild-Type GBS 515 with pLZ12-
rofA-pro vector, ΔCpsA GBS 515 with pLZ12-rofA-pro vector, and ΔCpsA GBS 515 
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with the mutant cpsA plasmid were grown in THYB broth supplemented with 
Chloramphenicol (3ug/mL).   
 
2.6.2 Bacterial Dosage 
 Overnight bacterial cultures were subcultured at a dilution of 1:20 into THYB 
supplemented with Chloramphenicol (3ug/mL). Subcultures were incubated at 37℃ until 
the culture reached the mid-log phase of growth. Subcultures were normalized to an 
OD600 of 0.225. Following normalization, 1 mL of each cell sample was pelleted via 
centrifugation at 14,000 RPM for 5 minutes. The supernatant was then removed, and the 
pellet was resuspended in 1 mL of sterile THYB. The sample was pelleted and 
resuspended again in the same manner and then placed on ice. The cell samples should 
now be at a concentration of 1 x 10^8 CFU/mL. 
 
2.6.3 Inoculum Dose Verification 
Each of the tested groups were serially diluted out to 10^-7 and 100uL of the 10^-
6 and 10^-7 dilutions were plated on THY Agar-Chloramphenicol (3ug/mL) plates. The 
plates were incubated for 24 hours at 37℃ in 5% CO2 and then counted to verify that the 
concentration of the cell samples were 1x10^8 CFU/mL. 
 
2.6.4 Microinjections into the Yolk Sac 
 Dechorionated embryos were anesthetized by placing them in 25 mL of fish 
embryo water supplemented with 2mL of Tricaine. A microinjector needle was cut and 
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calibrated to release ~1nL of the cell suspension per injection. Fish were injected with 
100 CFU (1nL of 1x10^8 CFU/mL) of each strain or with sterile media as a negative 
control. Once the needle was loaded with the correct dose + 0.1% phenol red, 
anesthetized fish embryos were stabilized in methylcellulose on an agar injection plate. 
The fish were then injected in the lower part of their yolk sacs and washed into fresh fish 
water without tricaine to rinse off the methylcellulose. The fish were then immediately 
placed into a well of a 6-well plate. This procedure was repeated for each of the tested 
groups, using 20 zebrafish larvae for each experimental group and 10 zebrafish larvae for 
the negative control group (sterile media). The zebrafish were then incubated at 27-29℃ 
and monitored for survival over a period of 72 hours, removing any dead larvae as the 
monitoring progressed. 
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3. RESULTS 
3.1 Chain Length Analysis using Microscopy 
 GBS chain lengths are dependent on cell wall interactions (14). For this reason, if 
the LytR Domain mutations influence cell wall stability and CpsA ligation to the cell 
wall, then a change in chain length phenotype may be displayed in the mutant GBS 
strain. Analysis of the chain lengths of each experimental strain of GBS 515 revealed that 
the wild-type chain length frequency (Figure 4A) remained consistent with the expected 
short-chain phenotype. As demonstrated in previous research (1), the ΔcpsA GBS chain 
length frequency (Figure 4B) remained consistent with the expected long-chain 
phenotype. Wild-Type-pmutantcpsA (Figure 4C) and ΔcpsA-pmutantcpsA (Figure 4D) 
strains exhibited short-chain phenotypes. A comparison of the average chain length 
between experimental groups (Figure 5E) displayed that the wild-type GBS strain had an 
average chain length of ~2.79 cocci, which is consistent with the normal amount of cocci 
seen in wild-type GBS (1). The ΔcpsA GBS strain had an average chain length of ~9.92 
cocci, consistent with the long chain phenotype seen in the cpsA deletion strain (8). Wild-
Type-pmutantcpsA strain had an average chain length of ~3.84 cocci and the ΔcpsA-
pmutantcpsA strain had an average chain length of ~2.9 cocci. Statistical analysis of the 
data reveals that the average chain length of the ΔcpsA-pmutantcpsA strain complimented 
the average chain length of the wild-type GBS strain. Additionally, the data revealed that 
the increase in average chain length of the Wild-Type-pmutantcpsA, as compared to the 
wild-type strain, are statistically significant; However, with an average chain length of 
3.84, the Wild-Type-pmutantcpsA strain has a chain length of between 2 and 4 cocci, 
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which is in the range of a normal, short-chain phenotype as exhibited by wild-type in a 
previous study (1). The short-chain phenotypes demonstrated by the mutant cpsA strains 
of GBS suggest that the D375A and R378A mutations are not effective in altering the 
functionality of the LytR Domain and therefore the cell wall interactions of GBS. 
 
 
Figure 4. Chain length frequency of experimental GBS 515 strains. Five fields of view 
per group were analyzed to calculate the chain length distribution of each experimental 
group. A) Chain length frequency of Wild-Type GBS 515 strain containing an empty 
plasmid. B) Chain length frequency of ΔcpsA GBS 515 strain containing an empty 
plasmid. C) Chain length frequency of Wild-Type GBS 515 strain containing a mutant 
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cpsA plasmid. D) Chain length frequency of the ΔcpsA GBS 515 strain containing a 
mutant cpsA plasmid. 
 
Figure 5. Effect of mutations on chain length. Analysis of overnight GBS cultures of 
Wild-Type with an empty plasmid (A), ΔcpsA with an empty plasmid (B), Wild-Type 
with a mutated ΔcpsA plasmid (C), and ΔcpsA with a mutated ΔcpsA plasmid (D) by 
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microscopy was performed. Five fields of view for each experimental group were 
visualized and the average number of cocci per chain was calculated (E). WT-pempty has 
an average chain length of 2.79 cocci, ΔcpsA-pempty has an average chain length of 9.92 
cocci, WT-pmutantcpsA has an average chain length of 3.84 cocci, and ΔcpsA-
pmutantcpsA has an average chain length of 2.90 cocci. Error bars represent the standard 
error. **, P<0.01. N.S., P=0.695. 
 
3.2 Capsule Quantification through an Enzyme-Linked Immunosorbent Assay 
An Indirect Enzyme Linked Immunosorbent Assay (ELISA) was used to quantify 
the amount of capsule expressed in the experimental GBS 515 groups. If the D375A and 
R378A mutations were effective in reducing capsule production or capsular ligation to 
the cell wall, then there should be an overall decrease in capsule expression when 
comparing the mutant strains of GBS to the wild-type strain. ELISA results of each 
experimental GBS 515 group revealed that Wild-Type-pempty has significantly more 
capsule present than ΔcpsA-pempty (Figure 6). The Wild-Type-pmutantcpsA GBS strain 
displayed an expression of 5992.29 capsular units and the ΔcpsA-pmutantcpsA GBS 
strain displayed an expression of 6280.153 capsular units. In comparison to the Wild-
Type-pempty strain, which expressed 6514.8 capsular units, the capsular levels of the 
Wild-Type-pmutantcpsA and the ΔcpsA-pmutantcpsA strains were decreased, however 
the decreases were not statistically significant to confirm a correlation by the effects of 
the mutations. These results suggest that the D375A and R378A mutations are not 
effective in decreasing the amount of capsule that is expressed on the cell wall of GBS. 
The results of this data are based on a single experiment consisting of three dilutions, 
with each dilution performed in triplicate, and therefore further ELISA trials are required 
to confirm the accuracy of the presented data. 
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Figure 6. Comparison of levels of capsule present in GBS experimental groups. Capsule 
levels were calculated using the average of nine ELISA results per group, after 
subtracting background quantities. Error bars represent the standard error. **, P<0.02. 
N.S., P>0.10. 
3.3 Changes in Cell Wall Morphology 
 The Fluorescent Vancomycin Assay was performed to determine the effect that 
the D375A and R378A mutations have on the cell wall morphologies of GBS. If D375 
and R378 play a significant role in cell wall stability, then the mutant strains of GBS 
should display as having abnormal cell wall morphologies. Results of the Fluorescent 
Vancomycin Assay show that the cell wall morphologies of the Wild-Type-pempty GBS 
515 strain are relatively stable, indicated by a bright ring of green fluorescence 
surrounding the individual cocci (Figure 7A). A cpsA deletion in GBS 515 causes cell 
wall abnormalities and instability, demonstrated by cocci that are equally fluorescent 
throughout, indicative of a leaky cell wall (Figure 7B). The Wild-Type-pmutantcpsA and 
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ΔcpsA-pmutantcpsA GBS 515 strains display varying results, with most cells in the 
observed fields of view displaying stable cell walls, similar to the results demonstrated by 
the Wild-Type-pempty GBS 515 strain (Figures 7C and 7D). Further experimentation and 
analysis is necessary to accurately quantify the overall cell wall stability of the GBS 
strains. 
 
 
Figure 7. Effects of mutations on GBS cell wall morphology. The cell wall morphologies 
of Wild-Type-pempty (A), ΔcpsA-pempty (B), Wild-Type-pmutantcpsA (C), and ΔcpsA-
pmutantcpsA (D) were observed by fluorescent microscopy after incubating with 1ug/uL 
BODIPY_FL Vancomycin (ThermoFisher Scientific). 
 
3.4 Zebrafish Survivability Assay 
Previous research shows that a cpsA deletion strain of GBS has an attenuated 
virulence in a zebrafish model of infection (1). Therefore, cpsA expression and 
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functionality is shown to be a key determinant in the infectivity of GBS. To test if the 
D375A and R378A mutations are effective in reducing the virulence of GBS, zebrafish 
larvae were infected with ~100 CFU of the experimental GBS strains and monitored for 
their survivability. If the D375A and R378A mutations reduce GBS virulence, then there 
should be an increased survivability compared to wild-type GBS infected zebrafish. 
Zebrafish infection results reveal that the ΔcpsA-pmutantcpsA GBS 515 strain is 
comparable to the ΔcpsA-pempty GBS 515, yet to a lesser extent (Figure 8).  Twenty-
Four hours post-infection, 70% of Wild-Type-pempty, 95% of ΔcpsA-pempty, and 75% 
of the ΔcpsA-pmutantcpsA injected zebrafish were alive. However, 48 hours and 72 hours 
post-infection, while all the Wild-Type-pempty GBS 515-infected fish had succumbed to 
the infection, 30% of the ΔcpsA-pempty, and 25% of the ΔcpsA-pmutantcpsA groups had 
survived the infection. These results demonstrate that the mutations created in cpsA may 
influence GBS virulence. The results of this experiment were compiled from a single 
trial, using 20 zebrafish per experimental group, and therefore the experiment needs to be 
repeated to confirm the effects of the mutations. Further trials are required to determine if 
the data is statistically significant. 
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Figure 8. Effects of mutations on GBS virulence. Experimental strains were injected into 
zebrafish at a volume of 1nl, which was ~100 CFU. Every 24 hours, over a period of 72 
hours, living fish were counted and a percentage of the surviving fish was recorded. 
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4. DISCUSSION 
Despite medical advancements, such as pre-screening and intrapartum antibiotic 
prophylaxis (IAP), GBS infections remain a predominant cause of early-onset disease in 
neonates (15). Additionally, the incidence of invasive GBS infections in adults has 
increased over the past eleven years, most likely due to the increase in a prevalence of 
chronic diseases, such as diabetes and obesity (16). Current treatments for GBS infection 
include common antibiotics, such as penicillin, administered during labor, delivery, or 
after diagnosis of GBS infection. Antibiotics, however, are not a lasting treatment as 
antibiotic resistance becomes more prevalent in GBS populations (16). For this reason, 
new therapies targeting GBS virulence factors, such as capsular polysaccharide and β-
hemolysin, are being researched (17). 
The streptococcal CpsA protein is a member of the LytR-CpsA-Psr (LCP) family; 
a multifunctional family of proteins involved in attaching carbohydrates, capsular 
polysaccharide, and teichoic acids to the cell wall in various Gram-positive bacterial 
populations (1). Although the major functions of the LCP family have been identified, the 
mechanisms by which the LCP family functions is still mostly unknown.  
CpsA is a putative transcriptional regulator of the capsule locus and is therefore 
an integral cog in the capsule-regulating machine. In a previous experiment, an in-frame 
deletion of cpsA, the protein-coding gene of CpsA, was performed in GBS which resulted 
in reduced levels of capsule (18), reinforcing the significance of the gene. The GBS 
capsule is one of the key virulence factors contributing to the pathogenicity of GBS. The 
capsule functions as a protective layer surrounding the cell, aiding in evasion of host 
immune responses and the binding of host cells. Hanson et al, demonstrated that a ΔcpsA 
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strain of GBS 515 had reduced levels of capsule, as well as a significantly reduced 
virulence in a zebrafish infection model (14). 
The CpsA protein contains three major domains: an intracellular DNA-binding 
domain, an extracellular accessory domain, and an extracellular LytR domain. The LytR 
domain, predicted to be involved in capsular attachment and cell wall stability, was the 
central focus of this study. Kawai et al elucidated the crystal structure of the LytR domain 
in the CpsA protein of Streptococcus pneumoniae and determined which residues were 
potentially essential to its function (11). In their work, they found a lipid molecule buried 
in the LytR domain active site, leading them to suggest that this domain may play a key 
role in the ligation of CPS to the cell wall. Due to the significant homology between S. 
pneumoniae and GBS, the crystal structure solved by Kawai was used as a guide to 
discern which residues should be mutated in the GBS cpsA gene. Aspartic Acid-375 and 
arginine-378 in GBS, correlating to aspartic acid-371 and arginine-374 in S. pneumoniae, 
are predicted to interact with one another in order to form and stabilize a positively 
charged pocket containing the phosphate head group of the buried lipid (11). Aspartic 
Acid is a negatively charged, polar amino acid, and arginine is a positively charged, polar 
amino acid. Due to the properties of these amino acids, along with the proximity between 
the two residues as displayed in the Cps2A crystal structure (Figure 3), it is predicted that 
there may be an attraction between D375 and R378, contributing to the protein-folded 
structure of CpsA in GBS (11). In this study, D375 and R378 were both mutated to 
alanine molecules. Alanine is a small, neutral, and hydrophobic molecule. In replacing 
the two oppositely-charged amino acids with neutral molecules, potential interactions 
between the original two residues may be decreased, thus reducing the stability of the 
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phosphate head group interaction with the positively-charged pocket within the LytR 
active site. In doing so, experimental analysis of the mutant cpsA strains can be used to 
elucidate the mechanism behind the functions of the buried lipid within the LytR domain. 
The chain length of GBS is determined by various factors, such as the production 
of autolysins. All the factors contributing to GBS chain length are not known, however 
capsular levels have been demonstrated to also be a factor (14). Due to the role that CpsA 
plays in capsular levels of GBS, microscopy analysis of the cpsA mutant strains of this 
study were performed (Figure 4). Wild-Type-pempty and ΔcpsA-pempty GBS 515 strains 
were significantly consistent with the respective short-chain and long-chain phenotypes 
demonstrated in the literature (14), with a p-value of less than 0.01. In comparing the 
Wild-Type-pmutantcpsA and ΔcpsA-pmutantcpsA GBS strains to the empty plasmid 
strains, it was determined that the mutant strains were not consistent with the ΔcpsA-
pempty GBS 515 strain. Additionally, the ΔcpsA-pmutantcpsA strain displayed as having 
an average capsular level like that of the Wild-Type-pempty GBS 515 strain (Figure 6).  
The comparable results of the ΔcpsA-pmutantcpsA strain to the Wild-Type strain may 
allude to the failure of the D375A and R378A mutations to significantly affect capsular-
cell wall interactions within GBS. This, however, is contradicted in the comparison of the 
Wild-Type-pmutantcpsA strain to the Wild-Type-pempty strain. Microscopy results 
revealed that the average chain length of the Wild-Type-pmutantcpsA strain was still 
significantly less than that of the ΔcpsA-pmutantcpsA strain, but slightly larger than the 
Wild-Type-pempty strain. Although these results are variable, the differences are not 
substantial enough to resemble the ΔcpsA-pmutantcpsA strain and additionally, the results 
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of the chain length analysis are comparable to the expected chain length analysis results 
of wild-type GBS in previous research (1). 
The Enzyme-Linked Immunosorbent Assay data of this study similarly 
demonstrates the ineffectiveness of the mutations to significantly affect capsular 
interactions that would result in reduced levels of attached capsule. As described in 
previous literature, ΔcpsA-pempty GBS 515 strain had significantly reduced levels of 
capsule when compared to the Wild-Type-pempty strain (Figure 6). Further ELISA trials 
are required to confirm the accuracy of the presented data. 
The LytR domain is predicted to have functions in capsular attachment to the cell 
wall as well as in cell wall stability. If mutations in the LytR domain reduced the 
regulation of cell wall stability in GBS, then the cell wall of GBS would be abnormally 
formed, unstable, and non-uniform. A fluorescent vancomycin assay was performed as a 
means of visualizing the cell walls of each of the experimental groups (Figure 7). 
Fluorescently-tagged vancomycin binds to the cell wall of GBS and is unable to penetrate 
through the bacteria, unless the cell wall is unstable. This is demonstrated in a 
comparison between the Wild-Type-pempty and ΔcpsA-pempty GBS 515 strains. The 
Wild-Type-pempty strain displays as round cocci, with fluorescent green rings 
surrounding many of the bacteria (Figure 7A). This differs from the ΔcpsA-pempty GBS 
515 strain which demonstrated as having variable results, with many of the cocci 
fluorescing all throughout, indicating a weak and leaky cell wall (Figure 7B). Results of 
the mutant strains also reveal varying phenotypes; however, many of the cocci are normal 
and resemble the Wild-Type-pempty phenotype. This data supports the previous evidence 
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that the D375A and R378A mutations do not have a significant, negative effect on 
capsular-cell wall interactions within GBS 515. 
Ultimately, cpsA mutations are being constructed and analyzed to better 
understand the function of the GBS CpsA protein in expression of capsular 
polysaccharide. In doing so, mutated GBS with reduced levels of capsule are not as 
virulent in hosts that don’t have a developed immune system (1). Larval zebrafish 
infections of mutant GBS were used in this study to test the virulence of the experimental 
GBS 515 strains. Larval zebrafish are excellent model organisms of infection to 
demonstrate the effect of pathogens on a host without an adaptive immune system, such 
as human neonates. In this study, experimental strains of GBS 515 were injected into 
twenty zebrafish per strain at a volume of 1nl, which was ~100 CFU. The GBS injections 
were performed in the yolk-sac of the zebrafish to create a systemic GBS infection. The 
zebrafish were monitored for survivability over a period of 72 hours. As predicted, over a 
72-hour period, the Wild-Type-pempty GBS infections led to the complete death of all 
tested zebrafish and the ΔcpsA-pempty GBS infections led to a greater level of 
survivability at a 30% survival rate. Interestingly, the ΔcpsA-pmutantcpsA GBS strain 
displayed a 25% survival rate of the infected zebrafish population. The survivability 
assay was only performed once, and further trials are required to determine if the data is 
statistically significant. 
The lack of significant changes in capsular levels, cell wall stability, and capsular 
interactions demonstrated in this study confirm that the D375A and R375A mutations 
were not an effective means of decreasing GBS 515 virulence. Future experimentation to 
further elucidate the role of the buried lipid in the LytR domain of GBS CpsA would be 
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to mutate other significant residues that interact to form the positively-charged pocket of 
the LytR domain. Additionally, mutating amino acid residues that have an attractive 
relationship (aspartic acid and arginine) to residues that have a repulsive relationship may 
have an increased effect on altering the folding and functionality of the LytR domain. 
Research is currently being conducted to further characterize the capsular interactions of 
GBS and the amino acid residues that are essential to the functions of CpsA (Melody 
Neely, University of Maine, Orono, ME, USA). In its entirety, the research performed in 
this study helps to provide additional insights to the function of the LytR domain of the 
CpsA protein. Specifically, it helps to specify which residues may be key to decreasing 
the virulence of GBS and may provide information beneficial to the development of 
future GBS infection treatments. 
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